SuviCa is interested in business relationships with companies seeking opportunities in oncology. We offer compounds demonstrating a unique mechanism of action with potential therapeutic opportunities in a number of indications. The lead compound has been studied extensively in in vitro and in vivo models of cancer. The preclinical data has been generated by a world class group of research and clinical scientists who have functioned as a team on multiple projects. SuviCa’s technology has been recognized as important by scientific and business reviewers at state and federal bodies who have provided financial support. The ideal partner(s) would be an organization having research and clinical experience in oncology with a willingness to support a unique approach in the treatment of cancer.